Protalix BioTherapeutics, Inc. (PLX) Financials

PLX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 102.3 million 35.1 million
Dec. 31, 2025 82.3 million 34.1 million
Sept. 30, 2025 82.3 million 29.4 million
June 30, 2025 78.5 million 28.6 million

PLX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 21.3 million 532000
Dec. 31, 2025 3.3 million -1.6 million
Sept. 30, 2025 -4.2 million 598000
June 30, 2025 -5.7 million 427000

PLX Net Income

No data available :(

PLX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 51.8 million - 7.0 million
Dec. 31, 2025 30.3 million - 8.3 million
Sept. 30, 2025 29.4 million - 6.8 million
June 30, 2025 33.4 million - 5.3 million

PLX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 83.0 million
Dec. 31, 2025 78.5 million
Sept. 30, 2025 80.8 million
June 30, 2025 81.3 million

PLX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 761000 5.4 million 3.1 million 7.4 million
Dec. 31, 2025 1.2 million 5.6 million 3.5 million 8.7 million
Sept. 30, 2025 498000 4.5 million 2.9 million 17.7 million
June 30, 2025 431000 6.0 million 2.6 million 15.4 million

PLX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 33.8 million 4.1 million
Dec. 31, 2025 9.1 million 4.6 million
Sept. 30, 2025 17.9 million 8.3 million
June 30, 2025 15.7 million 5.9 million

PLX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

PLX

Price: $2.01

52 week price:
1.32
3.19

Earnings Per Share: 0.19 USD

P/E Ratio: 10.05

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 637200

Market Capitalization: 153.9 million

Links: